title: Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?
abstract: In the human systemic amyloidoses caused by mutant or wild-type transthyretin (TTR), deposition occurs at a distance from the site of synthesis. The TTR synthesized and secreted by the hepatocyte circulates in plasma, then deposits in target tissues far from the producing cell, a pattern reproduced in mice transgenic for multiple copies of the human wild-type TTR gene. By 2 yr of age, half of the transgenic males show cardiac deposition resembling human senile systemic amyloidosis. However, as early as 3 mo of age, when there are no deposits, cardiac gene transcription differs from that of nontransgenic littermates, primarily in the expression of a large number of genes associated with inflammation and the immune response. At 24 mo, the hearts with histologically proven TTR deposits show expression of stress response genes, exuberant mitochondrial gene transcription, and increased expression of genes associated with apoptosis, relative to the hearts without TTR deposition. These 24-mo-old hearts with TTR deposits also show a decrease in transcription of inflammatory genes relative to that in the younger transgenic mice. After 2 yr of expressing large amounts of human TTR, the livers of the transgenic mice without cardiac deposition display chaperone gene expression and evidence of an activated unfolded protein response, while the livers of animals with cardiac TTR deposition display neither, showing increased transcription of interferon-responsive inflammatory genes and those encoding an antioxidant response. With time, in animals with cardiac deposition, it appears that hepatic proteostatic capacity is diminished, exposing the heart to a greater load of misfolded TTR with subsequent extracellular deposition. Hence systemic (cardiac) TTR deposition may be the direct result of the diminution in the distant chaperoning capacity of the liver related to age or long-standing exposure to misfolded TTR, or both.
authors.affiliation: Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA. jbux@scripps.edu
authors.forename: Joel N
authors.initials: JN
authors.lastname: Buxbaum
authors.forename: Clement
authors.initials: C
authors.lastname: Tagoe
authors.forename: Gloria
authors.initials: G
authors.lastname: Gallo
authors.forename: John R
authors.initials: JR
authors.lastname: Walker
authors.forename: Sunil
authors.initials: S
authors.lastname: Kurian
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Salomon
mesh_terms: D000375:Aging / Q000235:genetics; D000686:Amyloidosis / Q000503:physiopathology*; D000818:Animals; D004195:Disease Models, Animal; D015870:Gene Expression; D006801:Humans; D000075363:Immunoglobulin Light-chain Amyloidosis; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D018832:Molecular Chaperones / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D011228:Prealbumin / Q000235:genetics / Q000378:metabolism*; D056811:Unfolded Protein Response
chemical_list: D018832:Molecular Chaperones; D011228:Prealbumin